Immunovia AB (OSTO:IMMNOV) Additional Paid-In Capital : kr1,220.77 Mil(As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Additional Paid-In Capital?

Immunovia AB's quarterly additional paid-in capital stayed the same from Sep. 2024 (kr1,186.06 Mil) to Dec. 2024 (kr1,186.06 Mil) but then increased from Dec. 2024 (kr1,186.06 Mil) to Mar. 2025 (kr1,220.77 Mil).

Immunovia AB's annual additional paid-in capital increased from Dec. 2022 (kr1,016.37 Mil) to Dec. 2023 (kr1,136.48 Mil) and increased from Dec. 2023 (kr1,136.48 Mil) to Dec. 2024 (kr1,186.06 Mil).

Immunovia AB Additional Paid-In Capital Historical Data

The historical data trend for Immunovia AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Additional Paid-In Capital Chart

Immunovia AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,015.29

1,015.73

1,016.37

1,136.48

1,186.06

Immunovia AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,136.48	1,136.48	1,186.06	1,186.06	1,220.77

Immunovia AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Immunovia AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

0G8X:UK 1YR:Germany

Address

Medicon Village, Scheelevagen 8, Lund, SWE, 223 63

Website

https://www.immunovia.com

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines